Meeting
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
Authors
E. Antonio Chiocca
Brigham and Women's Hospital, Boston, MA
E. Antonio Chiocca , Rimas Vincas Lukas , Clark C Chen , Ganesh Rao , Christina Amidei , Jill Yannetti Buck , Nira Hadar , Nathan A. Demars , John Miao , Taylor Estupinan , John W. Loewy , Yunxia Wang , Arnold Bruce Gelb , Laurence JN Cooper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT03636477
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2510)
DOI
10.1200/JCO.2020.38.15_suppl.2510
Abstract #
2510
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca
Poster
2016 ASCO Annual Meeting
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
First Author: Francois M. Lebel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC).
First Author: Bruno Sangro
Poster
2022 ASCO Annual Meeting
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
First Author: Mehmet Akce